The CamDiab CamAPS FX automated insulin delivery (AID) system produced better outcomes for pregnant women with type 1 diabetes in a clinical study.
Medscape reported that data came from the largest randomized controlled trial pitting an AID system against standard insulin delivery in pregnant women with type 1 diabetes. The automated CamAPS FX came out on top. Percentage time spent in the pregnancy-specific target blood glucose range from 16 weeks gestation to delivery proved significantly higher. That range totaled 63-140 mg/dL (3.5-7.8 mmol/L).
Dr. Helen Murphy presented the findings in an e-poster session at the American Diabetes Association (ADA) 83rd Scientific Sessions. She said the hybrid closed-loop system demonstrated improved maternal glucose and stated all pregnant women with type 1 diabetes should have access. Murphy serves as a professor of medicine at the University of East Anglia and a clinician at Norfolk and Norwich University Hospital in the UK.
More about the CamDiab CamAPS FX platform
CamAPS FX is the only AID system approved in Europe and the UK for type 1 diabetes from age one and during pregnancy. It features integration capabilities with the Dexcom G6 and worked in tandem with the continuous glucose monitor in this study.
The platform also integrates with the FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump. It remains unavailable in the U.S.
According to Medscape, researchers think the findings offer evidence for the UK National Institute of Clinical Excellence (NICE) to recommend that all pregnant women with type 1 diabetes should have access to the CamAPS-FX system. Murphy said researchers require more data on glucose profiles to consider extending the technology to type 2 diabetes in pregnancy.
This article previously referenced the CamDiab platform’s integration with the Abbott FreeStyle Libre 3. The system also integrates with the Dexcom G6 and the study referenced in the article used that sensor. This article was updated to reflect this.